Syndax Pharmaceuticals Inc Total Liabilities
Syndax Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Syndax Pharmaceuticals Inc (SNDX) has total liabilities worth $688.55 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Syndax Pharmaceuticals Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Syndax Pharmaceuticals Inc (2011–2025)
Total liabilities of Syndax Pharmaceuticals Inc from 2011 to 2025. This chart illustrates how Syndax Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Syndax Pharmaceuticals Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Syndax Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Syndax Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Televisa S.A.B.
F:TLV
|
Germany | €122.08 Billion |
|
Avanos Medical Inc
NYSE:AVNS
|
USA | $268.00 Million |
|
Smartgroup Corporation Ltd
AU:SIQ
|
Australia | AU$437.33 Million |
|
North China Pharmaceutical Co Ltd
SHG:600812
|
China | CN¥14.52 Billion |
|
Beijing Urban Construction Investment & Development Co Ltd
SHG:600266
|
China | CN¥78.25 Billion |
|
U-Haul Holding Company
NYSE:UHAL
|
USA | $13.87 Billion |
|
First Mid Illinois Bancshares Inc
NASDAQ:FMBH
|
USA | $8.21 Billion |
|
Implenia AG
SW:IMPN
|
Switzerland | CHF2.47 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Syndax Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Syndax Pharmaceuticals Inc assets under control.
Liquidity & Leverage Metrics
Syndax Pharmaceuticals Inc Total Liabilities Ratios Explained
Syndax Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 45.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.98 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Syndax Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Syndax Pharmaceuticals Inc (2011–2025)
The table below shows the annual total liabilities of Syndax Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $465.08 Million | +6.50% |
| 2024-12-31 | $436.69 Million | +644.14% |
| 2023-12-31 | $58.68 Million | +97.01% |
| 2022-12-31 | $29.79 Million | -27.86% |
| 2021-12-31 | $41.29 Million | -14.74% |
| 2020-12-31 | $48.42 Million | +51.68% |
| 2019-12-31 | $31.93 Million | +3.35% |
| 2018-12-31 | $30.89 Million | -6.01% |
| 2017-12-31 | $32.87 Million | +32.13% |
| 2016-12-31 | $24.87 Million | +7.19% |
| 2015-12-31 | $23.20 Million | +25.22% |
| 2014-12-31 | $18.53 Million | +255.56% |
| 2013-12-31 | $5.21 Million | -83.08% |
| 2012-12-31 | $30.80 Million | +29.18% |
| 2011-12-31 | $23.84 Million | -- |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. Th… Read more